ACAD · NASDAQ · STOCK
ACADIA Pharmaceuticals (ACAD) Stock Analysis
$19.79
52W $19.32 – $30.96
62/100
$3.39B
8.8
0.89
Is ACAD Bullish or Bearish?
Bullish.
Innellis AI committee rates ACADIA Pharmaceuticals Inc. (ACAD) Buy with a composite score of 62/100
, based on 6 analysts with 50% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +12.78 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -7.22 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 47.0% yoy -- genuine top-line momentum. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- P/E of 8.9 is inexpensive for the broad market — Value
- ROE of 32.4% shows genuine earnings power backing the valuation — Value
- Revenue growing 47.0% YoY -- genuine top-line momentum — Growth
- EPS growing 96.5% YoY — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock — Risk
Bear Case
- RSI at 17 is in oversold territory (could mean either capitulation or a bounce setup) — Technical
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 24 -- oversold on the larger timeframe too — Technical
- Bollinger bandwidth of 59.7% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
62/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 19%
of 192 Healthcare peers
Value Analyst
bullish
70
/ 100 · High confidence
Classic value case: cheap on multiples with earnings power to back it up
+ P/E of 8.9 is inexpensive for the broad market
Growth Analyst
bullish
85
/ 100 · High confidence
Strong, accelerating growth with consistent execution
+ Revenue growing 47.0% YoY -- genuine top-line momentum
Technical Analyst
bearish
38
/ 100 · High confidence
Price action is deteriorating -- trend and/or momentum are working against this name
− RSI at 17 is in oversold territory (could mean either capitulation or a bounce setup)
Risk Analyst
neutral
58
/ 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
+ Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock
− Bollinger bandwidth of 59.7% signals elevated volatility
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
neutral
58
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 62.2 to 62.2.
- New bearish signals: 3 appeared.
- Bearish pressure eased: 3 signal(s) disappeared.
Analyst-level changes:
- Risk Analyst: +1 bearish signal(s).
- Technical Analyst: +2 bearish signal(s).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
17.1
Oversold
MACD Histogram
-0.181
Bearish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Hh Hl
Support
$19.69
Resistance
$23.07
Bollinger %B
0.28
Inside Bands
Price vs Moving Averages
EMA 9
$20.36
Below
EMA 21
$22.41
Below
EMA 50
$24.49
Below
EMA 200
$24.25
Below
Fundamental Analysis
Valuation
94
Growth
72
Profitability
100
Financial Health
100
Cash Flow
70
Valuation
P/E Ratio
8.8×
P/B Ratio
2.60×
PEG Ratio
0.13
Dividend Yield
0.00%
52W High
$30.96
52W Low
$19.32
Quality & Growth
ROE
3185.6%
ROA
2499.7%
Gross Margin
9113.2%
Operating Margin
758.5%
Revenue Growth YoY
—
Debt / Equity
0.06
AI Fundamental Assessment
P/E ratio of 8.8 (inexpensive relative to a 15-40x range); Price-to-book of 2.6x; PEG ratio of 0.1 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 31.9%; Return on assets of 25.0%; Net margin of 33.4%; Gross margin of 91.1%; Current ratio of 3.39 (healthy short-term liquidity); Debt-to-equity of 0.06; Free cash flow per share is positive (1.02); Most recent quarter beat estimates by 207.2%; EPS growth accelerating (-98.8% -> +800.0% QoQ); Analyst estimates falling over recent quarters
Get the Full ACAD Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →